JGC
VRDN icon

J. Goldman & Co’s Viridian Therapeutics VRDN Stock Holding History

J. Goldman & Co’s Portfolio VRDN Stock Details VRDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$305K Sell
15,598
-52,456
-77% -$1.56M 0.01% 564
2025
Q4 		$2.12M Sell
68,054
-1,972
-3% -$54.1K 0.06% 305
2025
Q3 		$1.51M Sell
70,026
-30,751
-31% -$555K 0.04% 300
2025
Q2 		$1.41M Sell
100,777
-17,817
-15% -$242K 0.03% 316
2025
Q1 		$1.6M Sell
118,594
-60,902
-34% -$1.04M 0.04% 323
2024
Q4 		$3.44M Buy
+179,496
New +$3.9M 0.09% 224
2024
Q3 		– Sell
-74,985
Closed -$976K – 633
2024
Q2 		$976K Buy
74,985
+30,721
+69% +$425K 0.03% 307
2024
Q1 		$775K Buy
+44,264
New +$858K 0.03% 291

Other funds holding VRDN

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
BG
Bellevue Group Kuesnacht, Switzerland $4.2B AUM 54.85% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
FFM
Fairmount Funds Management West Conshohocken, Pennsylvania $1.38B AUM 407.79% 1-Year Est. Return
VA
VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return
T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return
PBA
Paradigm Biocapital Advisors New York $4.89B AUM 251.12% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return